Evidence map›Paper›PMID 33674712›Full record

ReviewJournal of perinatology : official journal of the California Perinatal Association2021

80 Years of vision: preventing blindness from retinopathy of prematurity.

Edward H Wood, Emmanuel Y Chang, Kinley Beck, Brandon R Hadfield, Amy R Quinn, Clio Armitage Harper

Registry-linked trialOpen access · hybridAbstract readReview
In one paragraph

Review in Journal of perinatology : official journal of the California Perinatal Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06067958 (Intranasal Dexmedetomidine for Pain Management During Screening for Retinopathy of Prematurity), which is not on this map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06067958 phase3recruitingnot on this mapstarted 2023, after this paper: background citation

Intranasal Dexmedetomidine for Pain Management During Screening for Retinopathy of Prematurity: a Crossover Randomized Controlled Trial

TypeinterventionalSponsorAssaf-Harofeh Medical CenterRan2023 to 2025Enrolled30ConditionsRetinopathy of Prematurity, DexmedetomidineArmsDexmedetomidine, Saline
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Targeting endothelial ERG to mitigate vascular regression in retinopathies.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  12. Long-term visual function and refractive changes after vitrectomy for stage 4 retinopathy of prematurity.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Article
  13. Observational
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Edward H WoodByers Eye Institute, Horngren Family Vitreoretinal Center, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, USA.
Emmanuel Y ChangRetina and Vitreous of Texas, Houston, TX, USA.
Kinley BeckEyesight Ophthalmic Services, Portsmouth, NH, USA.
Brandon R HadfieldUniversity of Texas Health Science Center San Antonio, Department of Pediatrics, Division of Neonatology, San Antonio, TX, USA.
Amy R QuinnUniversity of Texas Health Science Center San Antonio, Department of Pediatrics, Division of Neonatology, San Antonio, TX, USA.
Clio Armitage HarperAustin Retina Associates, Austin, TX, USA. caharper@austinretina.com.ORCID http://orcid.org/0000-0001-5998-2705
The University of Texas Health Science Center at San Antonio · USCardiovascular Institute of the South · US

Funding

Stanford Vision Research CoreP30EY026877 · NEI · STANFORD UNIVERSITY · PI Jeffrey L Goldberg · 2017 to 2026
$8.0M
NEI NIH HHS P30 EY026877
6 · The paper itself

Abstract

Retinopathy of prematurity (ROP) is one of the leading yet preventable causes of childhood blindness worldwide. The purpose of this review is to provide a practical template for observational and treatment methods in order to reduce the overall incidence of any ROP and to improve both short-term and long-term outcomes once Type 1 ROP (treatable ROP) develops.

Indexed as

Retinopathy of PrematurityBlindnessHumansInfant, Newborn

Identifiers

PMID33674712
PMCPMC8225510
OpenAlexW3133572231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.